Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT04766177
Recruiting Phase 3

Role of Bumetanide in Treatment of Autism

NCT04766177 · tracked via the Priya Life Science Egypt tracker
Sponsor
Sherief Abd-Elsalam
Phase
Phase 3
Started
2021-01-01
Last updated
2021-02-23

Condition(s) studied

Autism

Investigational drug(s) / intervention(s)

BumetanidePlacebo

Bumetanide: bumetanide 0.5 mg twice daily

Placebo: placebo tablets twice daily

Study summary

Role of bumetanide in Autism

Eligibility

Sex
ALL
Min age
3 Years
Max age
12 Years
Healthy volunteers
No
Inclusion Criteria: 1. All patients with ASD diagnosed by CARS rating Scale⩾30. 2. Age of patients range between (3-12) years. Exclusion Criteria: * Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).

Primary outcome measure(s)

  • Number of patients with improved CARS score — 6 months
    the patients with improved CARS score

Trial sites (1)

FacilityCityRegionStatus
Sherief Abd-Elsalam Tanta Egypt Recruiting

More Sherief Abd-Elsalam trials in Egypt

Statins and ARBs on Rheumatoid Activity Recruiting
Role of Point of Care Ultrasound in Endotracheal Tube Placement Recruiting
Effect of Some Drugs on Rheumatoid Arithritis Activity Recruiting
Effect of Some Drugs on Liver Fibrosis Recruiting
Clinical Study Evaluating Beta Blockers Use and Fracture Risk in Patients With Primary Osteoporosis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04766177 on ClinicalTrials.gov ↗ ← All trials in Egypt